Celldex Therapeutics, Inc. (CLDX)

NASDAQ: CLDX · IEX Real-Time Price · USD
43.09
-0.62 (-1.42%)
Feb 2, 2023, 10:47 AM EST - Market open
-1.42%
Market Cap 2.03B
Revenue (ttm) 1.08M
Net Income (ttm) -105.99M
Shares Out 47.10M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 56,106
Open 43.81
Previous Close 43.71
Day's Range 42.09 - 44.35
52-Week Range 19.85 - 48.40
Beta 2.28
Analysts Buy
Price Target 65.62 (+52.29%)
Earnings Date Feb 27, 2023

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 10, 2008
Employees 132
Stock Exchange NASDAQ
Ticker Symbol CLDX
Full Company Profile

Financial Performance

In 2021, CLDX's revenue was $4.65 million, a decrease of -37.30% compared to the previous year's $7.42 million. Losses were -$70.51 million, 18.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $65.62, which is an increase of 52.29% from the latest price.

Price Target
$65.62
(52.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients - - Long term follow up of patients with chronic inducible ...

2 months ago - GlobeNewsWire

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

- Includes oral presentation for 1.5 mg/kg cold urticaria cohort -

2 months ago - GlobeNewsWire

Celldex to Participate in Upcoming November Investor Conferences

HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in No...

2 months ago - GlobeNewsWire

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

- Multiple clinical-stage programs on track for data updates in upcoming months -

3 months ago - GlobeNewsWire

Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 -

6 months ago - GlobeNewsWire

Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?

The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

7 months ago - Zacks Investment Research

Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?

Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

7 months ago - Zacks Investment Research

Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data

Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four pat...

7 months ago - Benzinga

Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.

7 months ago - Zacks Investment Research

Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study

Celldex Therapeutics Inc (NASDAQ: CLDX) announced interim data from Phase 1b trial of barzolvolimab in chronic spontaneous urticaria (CSU) refractory to antihistamines.  CSU is characterized by the oc...

7 months ago - Benzinga

Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile- -Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week ...

7 months ago - GlobeNewsWire

Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

8 months ago - Zacks Investment Research

Celldex Announces Two New Appointments to its Board of Directors

HAMPTON, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company's Board of Directors.

8 months ago - GlobeNewsWire

Celldex to Present at the 2022 Jefferies Global Healthcare Conference

HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Health...

8 months ago - GlobeNewsWire

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022

HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with ant...

9 months ago - GlobeNewsWire

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

9 months ago - GlobeNewsWire

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corpor...

1 year ago - GlobeNewsWire

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to dis...

1 year ago - GlobeNewsWire

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leer...

1 year ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prur...

1 year ago - GlobeNewsWire